13th Oct 2025 15:30
GSK plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Emma Walmsley | |||
b) | Position/status | Chief Executive Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.3921 | 29 | ||||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Diana Conrad | |||
b) | Position/status | Chief People Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.3921 | 5 | ||||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | James Ford | |||
b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.3921 | 11 | ||||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Sally Jackson | |||
b) | Position/status | SVP, Global Communications and CEO Office | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.3921 | 19 | ||||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Luke Miels | |||
b) | Position/status | Chief Commercial Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.3921 | 3 | ||||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | David Redfern | |||
b) | Position/status | President Corporate Development | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.3921 | 76 | ||||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Regis Simard | |||
b) | Position/status | President, Global Supply Chain | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.3921 | 29 | ||||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Philip Thomson | |||
b) | Position/status | President, Global Affairs | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.3921 | 48 | ||||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Deborah Waterhouse | |||
b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.3921 | 62 | ||||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Victoria Whyte | |||
b) | Position/status | SVP & Company Secretary | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.3921 | 58 | ||||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Sally Jackson | |||
b) | Position/status | SVP, Global Communications and CEO Office | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.4016 | 1 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Victoria Whyte | |||
b) | Position/status | SVP & Company Secretary | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.4016 | 123 | ||||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Iain Whyte | |||
b) | Position/status | PCA of Ms V Whyte (SVP & Company Secretary) | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.4016 | 1,152 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Emma Walmsley | |||
b) | Position/status | Chief Executive Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.4016 | 105.836 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Diana Conrad | |||
b) | Position/status | Chief People Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.4016 | 1,233.149 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | James Ford | |||
b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.4016 | 1,024.598
| ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Sally Jackson | |||
b) | Position/status | SVP, Global Communications and CEO Office | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.4016 | 453.008
| ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dylan Jackson | |||
b) | Position/status | PCA of Sally Jackson (SVP, Global Communications and CEO Office) | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.4016 | 140.210
| ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | David Redfern | |||
b) | Position/status | President Corporate Development | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.4016 | 6,278.135
| ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Regis Simard | |||
b) | Position/status | President, Global Supply Chain | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.4016 | 2,616.351
| ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Philip Thomson | |||
b) | Position/status | President, Global Affairs | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.4016 | 2,144.723
| ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Kate Thomson | |||
b) | Position/status | PCA of Philip Thomson (President, Global Affairs) | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.4016 | 109.382
| ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Deborah Waterhouse | |||
b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.4016 | 1,279.528
| ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Tony Wood | |||
b) | Position/status | Chief Scientific Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.4016 | 1,270.306
| ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Victoria Whyte | |||
b) | Position/status | SVP & Company Secretary | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.4016 | 1.332
| ||||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Elizabeth McKee Anderson | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$43.7375 | 26 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-10 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Charles Bancroft | |||
b) | Position/status | Senior Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$43.7375 | 340 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-10 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr Hal Barron | |||
b) | Position/status | Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$43.7375 | 28 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-10 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr Anne Beal | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$43.7375 | 34 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-10 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr Harry Dietz | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$43.7375 | 32 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-10 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr Jeannie Lee | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$43.7375 | 13 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-10 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr Vishal Sikka | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$43.7375 | 99 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2025-10-10 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
Related Shares:
Glaxosmithkline